Low dose verapamil as an adjunct therapy for medically refractory epilepsy – An open label pilot study

Epilepsy is a major public health problem that affects 0.6 –1% of the general population (World Health Organization, 2016). Most efforts are targeted to the development of increasing numbers of anti-epileptic drugs (AEDs) – more than 20 AEDs are used clinically today. However, despite the availability, 30–40% of patients do not respond to pharmacother apy and continue to have “uncontrolled” or “refractory” seizures – a condition termed drug-resistant epilepsy (Kwan et al., 2010).

Source: Epilepsy Research - August 3, 2016 Category: Neurology Authors: Jaishree Narayanan, Robert Frech, Shaun Walters, Vimal Patel, Roberta Frigerio, Demetrius M. Maraganore Tags: Short communication Source Type: research